6533b7d6fe1ef96bd1265db9
RESEARCH PRODUCT
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
Gérard MilanoValérie BoigePierre Laurent-puigJean FaivreAurélien De Reynièssubject
OncologyCancer Researchmedicine.medical_specialtyCetuximabAntineoplastic AgentsAntibodies Monoclonal HumanizedProto-Oncogene Proteins p21(ras)Text miningInternal medicineProto-Oncogene ProteinsmedicineCluster AnalysisHumansColorectal TumorsNeoplasm StagingOligonucleotide Array Sequence AnalysisCetuximabbusiness.industryGene Expression ProfilingPatient SelectionAntibodies MonoclonalSignature (logic)ErbB ReceptorsGene Expression Regulation NeoplasticTreatment OutcomeOncologyMutationras ProteinsbusinessColorectal NeoplasmsKras mutationmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2008-05-01 | Journal of clinical oncology : official journal of the American Society of Clinical Oncology |